A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME) (MIVI-II)
A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of DME.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Antwerpen, Belgium, 2020
- ZNA OCMW Antwerpen
-
Ghent, Belgium, B-9000
- University Hospital of Ghent
-
Leuven, Belgium
- University Hospital Leuven
-
-
-
-
-
Munich, Germany
- Ludwig Maximillian University
-
-
-
-
-
Milan, Italy
- University of Milan
-
Pisa, Italy
- Azienda Ospedaliero-Universitaria Pisana
-
Rome, Italy, 00168
- Institute of Ophtalmology, Policlinico A: Gemelli (University Hospital),Catholic University of Sacred Heart
-
Varese, Italy, 21100
- Ospedale di Circolo di Varese, Insubria University
-
-
-
-
-
Groningen, Netherlands, 9700 RB
- Academic hospital Groningen
-
Rotterdam, Netherlands, 3011 BH
- Het Oogziekenhuis Rotterdam
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Vall d'hebrón
-
Barcelona, Spain, 08022
- Institut de Microcirurgia Ocular de Barcelona
-
Santiago de Compostela, Spain
- Instituto Technologico de Oftalmologia SL.
-
-
-
-
-
Liverpool, United Kingdom, L7 8XP
- Royal Liverpool & Broadgreen Hospital
-
London, United Kingdom, EC1V 2PD
- Moorfields Eye Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria include:
- patients >18 years of age with Diabetic Macular Edema
Exclusion Criteria include:
- PVD present at baseline
- Vitreous hemorrhage
- Certain vitreoretinal conditions including proliferative disease, rhegmatogenous retinal detachment, and proliferative vitreoretinopathy (PVR)
- Patients who have had a vitrectomy in the study eye at any time
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Ocriplasmin 25µg
25µg ocriplasmin intravitreal injection versus sham injection
|
Intravitreal injection, single administration
Other Names:
|
|
EXPERIMENTAL: Ocriplasmin 75µg
75µg ocriplasmin intravitreal injection versus sham injection
|
Intravitreal injection, single administration
Other Names:
|
|
EXPERIMENTAL: Ocriplasmin 125µg
125µg ocriplasmin intravitreal injection versus sham injection
|
Intravitreal injection, single administration
Other Names:
|
|
SHAM_COMPARATOR: sham injection
Sham injection
|
Sham intravitreal injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PVD Induction
Time Frame: Day 14 post-injection
|
The primary efficacy variable was the proportion of patients with total posterior vitreous detachment (PVD) on Day 14 as determined by a masked central reading center (CRC) using 4-quadrant B-scan and optical coherence tomography (OCT)
|
Day 14 post-injection
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TG-MV-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.